Literature DB >> 20061545

Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs.

Maaike Te Lintel Hekkert1, Gregory P Dubé, Evelyn Regar, Martine de Boer, Pascal Vranckx, Wim J van der Giessen, Patrick W Serruys, Dirk J Duncker.   

Abstract

Because of their ability to perfuse remote regions and deliver oxygen, hemoglobin-based oxygen carriers (HBOCs) may be considered in the treatment of several ischemic conditions such as acute coronary syndromes or high-risk percutaneous intervention. Here we studied the effects of intracoronary infusion of ex vivo preoxygenated HBOC-201 during brief total coronary artery occlusion (CAOs) on myocardial oxygenation and left ventricular (LV) function in a large animal model and investigated the influence of HBOC-201 temperature and infusion rate on these effects. Thirteen open-chest anesthetized swine were instrumented for measurement of global and regional LV function and metabolism. CAOs were induced by inflating an intracoronary balloon catheter; preoxygenated HBOC-201 (12 g/dL) was infused distally through the central lumen of the balloon catheter. Animals underwent consecutive 3-min CAOs interspersed by 30 min of reperfusion, accompanied by different HBOC-201 infusion rates (0, 15, 23, 30, 40, and 50 ml/min) and/or two infusion temperatures (18 degrees C or 37 degrees C) in random order. CAO elicited immediate loss of systolic shortening (SS) in the ischemic region (19 +/- 1% at baseline vs. -3 +/- 2% at end of CAO), resulting in decreases in maximum rate of rise in LV pressure (15 +/- 5%) and stroke volume (12 +/- 4%; all P < 0.05). Balloon deflation resulted in marked coronary reactive hyperemia (to 472 +/- 74% of baseline), increases in coronary venous concentrations of adenosine + inosine (to 218 +/- 26% of baseline; both P < 0.05) and rapid restoration of SS toward baseline. HBOC-201 ameliorated the CAO-induced changes in SS, stroke volume, reactive hyperemia, and coronary venous adenosine + inosine. The effects were temperature and flow dependent with full preservation of SS at 50 ml/min HBOC-201 of 37 degrees C. In conclusion, intracoronary preoxygenated HBOC-201 preserved myocardial oxygenation and LV function in swine during CAO in a dose- and temperature-dependent manner. In our study setting, preoxygenated HBOC-201 can match the oxygen delivery role of endogenous blood in the heart on an almost equivalent-volume basis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061545     DOI: 10.1152/ajpheart.00667.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  4 in total

1.  Vital organ tissue oxygenation after serial normovolemic exchange transfusion with HBOC-201 in anesthetized swine.

Authors:  William W Muir; Govindasamy Ilangovan; Jay L Zweier; Paula F Moon-Massat; Virginia T Rentko
Journal:  Shock       Date:  2011-06       Impact factor: 3.454

2.  High-Dose Polymerized Hemoglobin Fails to Alleviate Cardiac Ischemia/Reperfusion Injury due to Induction of Oxidative Damage in Coronary Artery.

Authors:  Qian Yang; Wei Wu; Qian Li; Chan Chen; Ronghua Zhou; Yanhua Qiu; Ming Luo; Zhaoxia Tan; Shen Li; Gang Chen; Wentao Zhou; Jiaxin Liu; Chengmin Yang; Jin Liu; Tao Li
Journal:  Oxid Med Cell Longev       Date:  2015-06-16       Impact factor: 6.543

3.  Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow.

Authors:  André Uitterdijk; Tuncay Yetgin; Maaike te Lintel Hekkert; Stefan Sneep; Ilona Krabbendam-Peters; Heleen M M van Beusekom; Trent M Fischer; Richard N Cornelussen; Olivier C Manintveld; Daphne Merkus; Dirk J Duncker
Journal:  Basic Res Cardiol       Date:  2015-08-26       Impact factor: 17.165

Review 4.  New Applications of HBOC-201: A 25-Year Review of the Literature.

Authors:  Min Cao; Yong Zhao; Hongli He; Ruiming Yue; Lingai Pan; Huan Hu; Yingjie Ren; Qin Qin; Xueliang Yi; Tao Yin; Lina Ma; Dingding Zhang; Xiaobo Huang
Journal:  Front Med (Lausanne)       Date:  2021-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.